Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial – The Lancet Infectious Diseases Invited commentary: COVID-19 vaccines for children younger than 12 years: are we ready? – The Lancet Infectious Diseases   Commentary on Twitter NEW—A phase 1/2 clinical trial […]

The post Phase 1/2 RCT: CoronaVac is well tolerated and safe and induces strong humoral responses in children and adolescents aged 3–17 years. appeared first on Links Medicus.